Wet (Neovascular / Exudative) Macular Degeneration Pipeline Review, H2 2015 Now Available at iData Insights Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015 Summary Global Markets Direct s, Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Review, H2 2015, provides an overview of the Wet (Neovascular / Exudative) Macular Degeneration s therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Wet (Neovascular / Exudative) Macular Degeneration and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-inclass products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Wet (Neovascular / Exudative) Macular Degeneration - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Wet (Neovascular / Exudative) Macular Degeneration and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Wet (Neovascular / Exudative) Macular Degeneration products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Wet (Neovascular / Exudative) Macular Degeneration pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by 1
understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Wet (Neovascular / Exudative) Macular Degeneration Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline Devise corrective measures for pipeline projects by understanding Wet (Neovascular / Exudative) Macular Degeneration pipeline depth and focus of Indication therapeutics - Develop and design inlicensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Browse Complete Report with TOC http://www.idatainsights.com/reports-landingpage.php?id=179094/wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2015 To Get Sample Copy of Report visit http://www.idatainsights.com/reports-landingpage.php?id=179094/wet-neovascular-exudative-macular-degeneration-pipeline-review-h2-2015 Table of Contents Table of Contents 2 List of Tables 5 List of Figures 8 Introduction 9 Global Markets Direct Report Coverage 9 Wet (Neovascular / Exudative) Macular Degeneration Overview 10 Therapeutics Development 11 Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Overview 11 Pipeline Products for Wet (Neovascular / Exudative) Macular Degeneration - Comparative Analysis 12 Wet (Neovascular / Exudative) Macular Degeneration - Therapeutics under Development by Companies 13 Wet (Neovascular / Exudative) Macular Degeneration - Pipeline Products Glance 18 Late Stage Products 18 Clinical Stage Products 19 Early Stage Products 20 Wet (Neovascular / Exudative) Macular Degeneration - Products under Development by Companies 21
2
Wet (Neovascular / Exudative) Macular Degeneration - Companies Involved in Therapeutics Development 26 Aciont Inc. 26 Allergan Plc 27 Amakem NV 28 Apellis Pharmaceuticals, Inc. 29 Apexigen, Inc. 30 Applied Genetic Technologies Corporation 31 Avalanche Biotechnologies, Inc. 32 Benitec Biopharma Limited 33 BIOCAD 34 Boehringer Ingelheim GmbH 35 Charlesson LLC. 36 Chong Kun Dang Pharmaceutical Corp. 37 Circadian Technologies Limited 38 Clanotech AB 39 Clearside BioMedical, Inc. 40 Daiichi Sankyo Company, Limited 41 Eleven Biotherapeutics Inc. 42 Exonate Limited 43 F. Hoffmann-La Roche Ltd. 44 Formycon AG 45 GTx, Inc. 46 iCo Therapeutics Inc. 47 3
Icon Bioscience, Inc. 48 Kala Pharmaceuticals, Inc. 49 Mabion SA 50 Mitotech S.A. 51 Neurotech Pharmaceuticals, Inc. 52 Novartis AG 53 Ocular Therapeutix, Inc. 54 Ohr Pharmaceutical Inc. 55 Ophthotech Corp. 56 Oxford BioMedica Plc 57 PanOptica, Inc. 58 Pfenex Inc. 59 Pfizer Inc. 60 Quark Pharmaceuticals, Inc. 61 Regeneron Pharmaceuticals, Inc. 62 RegenxBio Inc. 63 RXi Pharmaceuticals Corporation 64 Santen Pharmaceutical Co., Ltd. 65 Sanwa Kagaku Kenkyusho Co., Ltd. 66 TRACON Pharmaceuticals, Inc. 67 TWi Pharmaceuticals, Inc. 68 Tyrogenex, Inc. 69 Xbrane Bioscience AB 70
4
Read More http://www.idatainsights.com/reports-landing-page.php?id=179094/wet-neovascularexudative-macular-degeneration-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965 Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future project.
5